Research programme: antiangiogenic therapeutics- Exonate

Drug Profile

Research programme: antiangiogenic therapeutics- Exonate

Alternative Names: EXN 169; Serine/threonine-protein kinase 1 inhibitors; SPHINXes; SRPK1 inhibitors

Latest Information Update: 10 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exonate
  • Class Small molecules
  • Mechanism of Action Cyclin-dependent kinase-activating kinase inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Wet age-related macular degeneration

Most Recent Events

  • 11 Jun 2018 Exonate plans a phase I trial for Wet age-related macular degeneration in 2020
  • 06 Feb 2017 Exonate announces intention to submit an application to regulatory authorities for clinical evaluation for Wet age-related macular degeneration
  • 06 Feb 2017 Exonate plans clinical trials for Wet age-related macular degeneration in early 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top